Radiotherapy of early breast cancer in scleroderma patients: our experience with four cases and a short review of the literature

Kyrgias, G.; Theodorou, K.; Zygogianni, Anna; Tsanadis, Konstantinos; Zervoudis, Stefanos; Tzitzikas, John; Koukourakis, Michael I.

doi:10.2147/bctt.s28412

Cited by 3 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 5 gives us a glimpse of prior literature describing radiation outcomes in scleroderma patients with breast cancer (7–13, 19–22). It is important to note that the majority of reports describe only one to four patients with scleroderma and breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer

Shah

Hirpara

Poelman

et al. 2018

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer

Shah

Hirpara

Poelman

et al. 2018

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…Fourteen case reports and series included a total of 21 patients. Only 4 patients developed severe acute adverse events, while 9 patients developed non-severe adverse events, and 10 did not develop any adverse effects 12,[14][15][16]32,[35][36][37][38][40][41][42]44,45 . Table 2.…”

Section: Radiotherapy Toxicity Outcomesmentioning

confidence: 99%

“…Late Reactions. Late adverse effects were reported in 25 articles which included 95 patients 12,[14][15][16][18][19][20][21][22][23]25,[32][33][34][35][36][37][38][39][40][41][42][43][44][45] . Fourteen case reports and series had a total of 23 patients.…”

Section: Radiotherapy Toxicity Outcomesmentioning

confidence: 99%

Effects of Radiotherapy for Malignancy in Systemic Sclerosis: A Systematic Review

Aboabat,

Aldohan,

Cheung

et al. 2024

J Rheumatol

View full text Add to dashboard Cite

ObjectiveConcerns regarding offering radiotherapy to systemic sclerosis (SSc) patients stem from the potential worsening of SSc manifestations and radiotherapy toxicity. We conducted a systematic review to evaluate the effects of radiotherapy on SSc outcomes and radiotherapy-related toxicity.MethodsMEDLINE, Embase, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials were searched for SSc and radiotherapy. Inclusion criteria were SSc diagnosis, subsequent cancer development, and radiotherapy exposure. Outcomes were SSc manifestations (cutaneous thickening, pulmonary fibrosis, and SSc flare) and radiotherapy toxicity (acute and late) utilizing Common Terminology Criteria for Adverse Events for grading. Grade 1 and 2 toxicities were categorized as non-severe and grade 3-5 as severe.ResultsOf 121 SSc patients undergoing radiotherapy (mean age 56.4 years, 83.3% female, median radiotherapy dose 50 Gy), most did not show worsened SSc skin thickening (92.7%) or pulmonary complications (90.3%) post-radiotherapy. In retrospective studies, the average rates of acute adverse effects were 57.3% for nonsevere and 25.8% for severe, while the rates of late adverse effects were 32.4% for non-severe and 24% for severe.ConclusionAlthough most SSc patients do not exhibit significant worsening of SSc manifestations post-radiotherapy, there is a variable risk of acute and late toxicity. These findings suggest that while radiotherapy may be a viable option for cancer patients with SSc, it requires caution.

show abstract

“…Considering the genetic disorder of PXE, external radiotherapy could be contraindicated in patients with breast cancer …”

Section: Introductionmentioning

confidence: 99%

“…Considering the genetic disorder of PXE, external radiotherapy could be contraindicated in patients with breast cancer. 3,4 In this clinical study, we presented a multi-disciplinary management for a patient with BC and PXE in which the use of intra-operative radiation therapy (IORT) has proved to be essential to avoid mastectomy. Quadrantectomy and sentinel lymph node biopsy is the gold standard treatment in this cases; however, the presence of PXE as comorbidity is a great limitation for external radiotherapy, such total mastectomy could be the unique surgical solution.…”

Section: Introductionmentioning

confidence: 99%

Intra-operative radiotherapy management for breast cancer treatment in patients with pseudoxanthoma elasticum: A case report

et al. 2017

View full text Add to dashboard Cite

Pseudoxanthoma elasticum is a systemic metabolic disease presenting calcifications and progressive fragmentation of elastic fibers. Actually, no targeted therapies are available for the treatment; only prevention of complications is possible. Classically, pseudoxanthoma elasticum is a "benign" disease, without cancer association. Herein, we reported a singular association of pseudoxanthoma elasticum with breast carcinoma, describing the clinical management, in particular intra-operative treatment, focusing on intra-operative radiotherapy since no specific guidelines are available in literature.

show abstract

Radiotherapy of early breast cancer in scleroderma patients: our experience with four cases and a short review of the literature

Cited by 3 publications

References 39 publications

Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer

Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients With Breast Cancer

Effects of Radiotherapy for Malignancy in Systemic Sclerosis: A Systematic Review

Intra-operative radiotherapy management for breast cancer treatment in patients with pseudoxanthoma elasticum: A case report

Contact Info

Product

Resources

About